Ardelyx Inc (ARDX)

$7.74 -0.05 (-0.64%)
Market Cap 1.87B
Revenue (ttm) 333.62M
Net Income (ttm) -39.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 41.32
Profit Margin -11.73%
Debt to Equity Ratio 1.31
Volume 3,209,300
Avg Vol 4,314,778
Day's Range N/A - N/A
Shares Out 242.97M
Stochastic %K 22%
Beta 0.56
Analysts Strong Sell
Price Target $14.50

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in Ju...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 745 1700
Address:
400 Fifth Avenue, Suite 210, Waltham, United States
findingthestock
findingthestock Feb. 4 at 2:59 AM
$ARDX
0 · Reply
Stock_Catcher
Stock_Catcher Feb. 4 at 2:24 AM
Wealthy Wednesday Watchlist Pt 10 $BURU $THAR $ARDX $UAVS $RUM Let's Find a 1000% Runner this week
1 · Reply
KevinDL
KevinDL Feb. 4 at 2:22 AM
$ARDX am I the only one that finds it interesting if not concerning that we don’t have a definitive earnings date? This is not like them. I’m not saying it’s a bad thing, but it is not their routine. Anyone??
2 · Reply
FerreroRocher
FerreroRocher Feb. 4 at 1:45 AM
$ARDX Management just added 21 new Gastroenterology sales positions. Now 30 total. https://jobs.jobvite.com/ardelyx/jobs?nl=1&fr=true#/category/1024 Looks like they are expanding the sales force once again. This is massive!
0 · Reply
Ohzipit
Ohzipit Feb. 4 at 12:31 AM
$ARDX RJ update today. Remains strong buy price target $19
1 · Reply
HiIdontcareThx
HiIdontcareThx Feb. 3 at 11:51 PM
$ARDX Added 6k shares today. I’m from the Jim Rogers school of investing. When I see money lying in the corner I go pick it up.
1 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 11:22 PM
$ARDX Screenshot 1) Ticker is on a ticking clock to seize momo at both upper channels and compression. Similarly to the move before BO speculation and PA jumped whole dollars before hand. PA is not floating on any true confluence trigger zone. I cant repeat this enough. This is floating due to the prior gapping within this zone and has no actual macro structure here unless 7.35 is retested. Today’s catalyst might seem random but powers that be need to seize momo. Screenshot 2) This is from 1/22/26 to explain to you what the movement on 1/23/26 is trying to do. 7.73 and 8.19 is both connected which is why the range is wide like that on 1/23/26. 7.73 is a timeframe designator and trying to indicate the auction is in urgency. It force 8.19 to trigger which opens the auction up before compression collapse. It delays the auction which you can see how the BB reacts on 1/23/26. Instead of collapsing it expands to delay. If this wants to expand it must hold 7.73 or it will retest 7.35
1 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 10:43 PM
$ARDX i got receipts so you can see it in entirety. Give me a few
1 · Reply
FerreroRocher
FerreroRocher Feb. 3 at 10:28 PM
$ARDX United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of IBSRELA® (tenapanor) and XPHOZAH® (tenapanor).
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 9:38 PM
$ARDX so ehh, TA with full scenarios or kick rocks?
2 · Reply
Latest News on ARDX
Ardelyx Receives New Patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 13 hours ago

Ardelyx Receives New Patent for Tenapanor

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Jan 28, 2026, 8:29 AM EST - 6 days ago

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Ardelyx: Assessment Of Acquisition Rumors

Jan 21, 2026, 1:04 PM EST - 13 days ago

Ardelyx: Assessment Of Acquisition Rumors

Ardelyx: IBSRELA Momentum Drives Opportunity

Jan 20, 2026, 6:14 AM EST - 14 days ago

Ardelyx: IBSRELA Momentum Drives Opportunity

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Jan 8, 2026, 8:30 AM EST - 26 days ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Nov 7, 2025, 4:05 PM EST - 3 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Nov 5, 2025, 8:00 AM EST - 3 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Ardelyx: Impressive Q3 Record Growth - Why I Buy

Nov 5, 2025, 4:24 AM EST - 3 months ago

Ardelyx: Impressive Q3 Record Growth - Why I Buy

Ardelyx: A Long Overdue Rally

Nov 4, 2025, 3:32 PM EST - 3 months ago

Ardelyx: A Long Overdue Rally

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Nov 4, 2025, 8:00 AM EST - 3 months ago

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 11:06 PM EDT - 3 months ago

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 30, 2025, 4:01 PM EDT - 3 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Oct 28, 2025, 8:01 AM EDT - 3 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 21, 2025, 8:00 AM EDT - 3 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:35 AM EDT - 4 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Oct 13, 2025, 8:30 AM EDT - 4 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:11 AM EDT - 5 months ago

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 4:42 PM EDT - 5 months ago

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Ardelyx to Participate in Upcoming Investor Conferences

Aug 25, 2025, 8:00 AM EDT - 5 months ago

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Aug 15, 2025, 6:17 AM EDT - 6 months ago

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:11 PM EDT - 6 months ago

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:08 PM EDT - 6 months ago

Ardelyx Announces Changes to the Executive Leadership Team

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:01 PM EDT - 6 months ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jul 21, 2025, 8:00 AM EDT - 7 months ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Jun 2, 2025, 4:05 PM EDT - 8 months ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 21, 2025, 8:00 AM EDT - 9 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 6, 2025, 8:01 AM EDT - 9 months ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

May 2, 2025, 10:07 AM EDT - 9 months ago

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

May 1, 2025, 10:06 PM EDT - 9 months ago

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:01 PM EDT - 9 months ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 29, 2025, 8:00 AM EDT - 10 months ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Apr 24, 2025, 8:01 AM EDT - 10 months ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 10 months ago

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Apr 10, 2025, 4:02 PM EDT - 10 months ago

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Mar 31, 2025, 4:03 PM EDT - 11 months ago

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Mar 13, 2025, 8:02 AM EDT - 11 months ago

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +

Mar 1, 2025, 8:30 AM EST - 1 year ago

Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +

HTLD NTR

Tenapanor Approved in China for Hyperphosphatemia

Feb 26, 2025, 7:00 AM EST - 1 year ago

Tenapanor Approved in China for Hyperphosphatemia

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)

Feb 24, 2025, 2:28 PM EST - 1 year ago

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 1 year ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

GERN MRNA PSNL TEM

findingthestock
findingthestock Feb. 4 at 2:59 AM
$ARDX
0 · Reply
Stock_Catcher
Stock_Catcher Feb. 4 at 2:24 AM
Wealthy Wednesday Watchlist Pt 10 $BURU $THAR $ARDX $UAVS $RUM Let's Find a 1000% Runner this week
1 · Reply
KevinDL
KevinDL Feb. 4 at 2:22 AM
$ARDX am I the only one that finds it interesting if not concerning that we don’t have a definitive earnings date? This is not like them. I’m not saying it’s a bad thing, but it is not their routine. Anyone??
2 · Reply
FerreroRocher
FerreroRocher Feb. 4 at 1:45 AM
$ARDX Management just added 21 new Gastroenterology sales positions. Now 30 total. https://jobs.jobvite.com/ardelyx/jobs?nl=1&fr=true#/category/1024 Looks like they are expanding the sales force once again. This is massive!
0 · Reply
Ohzipit
Ohzipit Feb. 4 at 12:31 AM
$ARDX RJ update today. Remains strong buy price target $19
1 · Reply
HiIdontcareThx
HiIdontcareThx Feb. 3 at 11:51 PM
$ARDX Added 6k shares today. I’m from the Jim Rogers school of investing. When I see money lying in the corner I go pick it up.
1 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 11:22 PM
$ARDX Screenshot 1) Ticker is on a ticking clock to seize momo at both upper channels and compression. Similarly to the move before BO speculation and PA jumped whole dollars before hand. PA is not floating on any true confluence trigger zone. I cant repeat this enough. This is floating due to the prior gapping within this zone and has no actual macro structure here unless 7.35 is retested. Today’s catalyst might seem random but powers that be need to seize momo. Screenshot 2) This is from 1/22/26 to explain to you what the movement on 1/23/26 is trying to do. 7.73 and 8.19 is both connected which is why the range is wide like that on 1/23/26. 7.73 is a timeframe designator and trying to indicate the auction is in urgency. It force 8.19 to trigger which opens the auction up before compression collapse. It delays the auction which you can see how the BB reacts on 1/23/26. Instead of collapsing it expands to delay. If this wants to expand it must hold 7.73 or it will retest 7.35
1 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 10:43 PM
$ARDX i got receipts so you can see it in entirety. Give me a few
1 · Reply
FerreroRocher
FerreroRocher Feb. 3 at 10:28 PM
$ARDX United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of IBSRELA® (tenapanor) and XPHOZAH® (tenapanor).
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 9:38 PM
$ARDX so ehh, TA with full scenarios or kick rocks?
2 · Reply
Quantumup
Quantumup Feb. 3 at 9:33 PM
Raymond James reiterated $ARDX at a Strong Buy rating and a $19 price target. Here's what Raymond James had to say: https://x.com/Quantumup1/status/2018798832230768702?s=20
1 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 9:03 PM
$ARDX am i right🫣
1 · Reply
MedHS55
MedHS55 Feb. 3 at 8:56 PM
$ARDX Nothing but bot/algo trades going into the close
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 8:41 PM
$ARDX dam lvls hit differently when its in a compression. Look man, we are in a time crunch. Shit cant be doing that again
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 8:25 PM
$ARDX 7.73 to fight off the darkness
0 · Reply
bowlerhatsftw
bowlerhatsftw Feb. 3 at 7:39 PM
$ARDX finally broke intraday downtrend
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Feb. 3 at 7:24 PM
$ARDX Ha ha. Posted yesterday. $NVO crashes today. WILL NOT AFFECT Ardelyx except ADDS value for Mott to sell in “ongoing negotiations “. Proof:
1 · Reply
Diddysjury
Diddysjury Feb. 3 at 6:52 PM
$ARDX macro dumpster fire
1 · Reply
Orion_Laverne
Orion_Laverne Feb. 3 at 6:26 PM
$ARDX Buy dips...hold....repeat
0 · Reply
TheYoungGeologist
TheYoungGeologist Feb. 3 at 6:21 PM
$ARDX shout-out to Novo Nordisk for destroying the bio market today
0 · Reply
CoachCut
CoachCut Feb. 3 at 6:12 PM
$ARDX how low can BTC go until it breaks everything???
0 · Reply
Food4Thought
Food4Thought Feb. 3 at 6:10 PM
$ARDX Trying out for ARDX PR team. Sample of what slide should look like on next quarterly presentation! Hopefully it will be updated.
0 · Reply